Hydralazine Disease Interactions
There are 6 disease interactions with hydralazine.
- Bone marrow suppression
- Coronary artery disease
- Lupus erythematosus
- Valvular heart disease
- Cerebral vasculopathy
- Renal dysfunction
Hydralazine (applies to hydralazine) bone marrow suppression
Major Potential Hazard, Low plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts
Hydralazine may rarely cause blood dyscrasias at recommended dosages. Reduction in hemoglobin, red cell count, agranulocytosis, leukopenia, and purpura have been reported. Therapy with hydralazine should be administered cautiously in patients with these preexisting conditions and if such abnormalities develop during the course of therapy, treatment should be discontinued. Monitoring blood counts should be considered for those patients at higher risk.
References
- Koch-Weser J (1976) "Hydralazine." N Engl J Med, 295, p. 320-3
- Orenstein AA, Yakulis V, Eipe J, Costea N (1977) "Immune hemolysis due to hydralazine." Ann Intern Med, 86, p. 450-1
- Widerlov E, Karlman I, Storsater J (1980) "Hydralazine-induced neonatal thrombocytopenia." N Engl J Med, 303, p. 1235
- Freestone S, Ramsay LE (1982) "Transient monoclonal gammopathy in hydralazine-induced lupus erythematosus." Br Med J, 285, p. 1536-7
- Macleod WN (1983) "Anaemia in the hydrallazine-induced lupus syndrome." Scott Med J, 28, p. 181-2
- Harrison BD, Laidlaw ST, Reilly JT (1995) "Fatal aplastic anaemia associated with lisinopril." Lancet, 346, p. 247-8
- (2001) "Product Information. Apresoline (hydralazine)." Ciba-Geigy Pharmaceuticals
Hydralazine (applies to hydralazine) coronary artery disease
Major Potential Hazard, High plausibility. Applicable conditions: Ischemic Heart Disease
The use of hydralazine is contraindicated in patients with coronary artery disease. Reflex tachycardia may commonly occur. Palpitations and chest pain have also been reported. Myocardial infarction has been associated with the use of hydralazine.
References
- Koch-Weser J (1976) "Hydralazine." N Engl J Med, 295, p. 320-3
- Laslett LJ, DeMaria AN, Amsterdam EA, Mason DT (1978) "Hydralazine-induced tachycardia and sodium retention in heart failure: hemodynamic and symptomatic correlation by prazosin therapy." Arch Intern Med, 138, p. 819-20
- Packer M, Meller J, Medina N, et al. (1981) "Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure." Am J Cardiol, 48, p. 939-46
Hydralazine (applies to hydralazine) lupus erythematosus
Major Potential Hazard, High plausibility.
The use of hydralazine has been associated with the development of lupus erythematosus and lupus-like syndromes, as well as exacerbation of the disease. Hydralazine therapy should be withdrawn in patients experiencing worsening of preexisting lupus. Monitoring complete blood counts, and antinuclear antibody titers before and during prolonged therapy is recommended.
References
- Hahn BH, Sharp GC, Irvin WS, et al. (1972) "Immune responses to hydralazine and nuclear antigens in hydralazine-induced lupus erythematosus." Ann Intern Med, 76, p. 365-74
- Carey RM, Coleman M, Feder A (1973) "Pericardial tamponade: a major presenting manifestation of hydralazine-induced lupus syndrome." Am J Med, 54, p. 84-7
- Perry HM (1973) "Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis." Am J Med, 54, p. 58-72
- Blumenkrantz N, Christiansen AH, Ullman S, Asboe-Hansen G (1974) "Hydralazine-induced lupoid syndrome." Acta Med Scand, 195, p. 443-9
- Weinstein J (1978) "Hypocomplementemia in hydralazine-associated systemic lupus erythematosus." Am J Med, 65, p. 553-6
- Freestone S, Ramsay LE (1982) "Transient monoclonal gammopathy in hydralazine-induced lupus erythematosus." Br Med J, 285, p. 1536-7
- Macleod WN (1983) "Anaemia in the hydrallazine-induced lupus syndrome." Scott Med J, 28, p. 181-2
- Ihle BU, Whitworth JA, Dowling JP, Kincaid-Smith P (1984) "Hydralazine and lupus nephritis." Clin Nephrol, 22, p. 230-8
- Cameron HA, Ramsay LE (1984) "The lupus syndrome induced by hydralazine: a common complication with low dose treatment." Br Med J, 289, p. 410-12
- Naparstek Y, Kopolovic J, Tur-Kaspa R, Rubinger D (1984) "Focal glumerulonephritis in the course of hydralazine-induced lupus syndrome." Arthritis Rheum, 27, p. 822-5
- Shapiro KS, Pinn VW, Harrington JT, Levey AS (1984) "Immune complex glomerulonephritis in hydralazine-induced SLE." Am J Kidney Dis, 3, p. 270-4
- Cush JJ, Goldings EA (1985) "Southwestern internal medicine conference: drug-induced lupus: clinical spectrum and pathogenesis." Am J Med Sci, 290, p. 36-45
- Innes A, Rennie JA, Cato GR (1986) "Drug-induced lupus caused by very-low-dose hydralazine." Br J Rheumatol, 25, p. 225-31
- Darwaza A, Lamey P-J, Connell JM (1988) "Hydrallazine-induced Sjogren's syndrome." Int J Oral Maxillofac Surg, 17, p. 92-3
- Sturman SG, Kumararatne D, Beevers DG (1988) "Fatal hydralazine-induced systemic lupus erythematosus." Lancet, 12/03/88, p. 1304
- Fleming MG, Bergfeld WF, Tomecki KJ, et al. (1989) "Bullous systemic lupus erythematosus." Int J Dermatol, 28, p. 321-6
- Ramsey-Goldman R, Franz T, Solano FX, Medsger TA (1990) "Hydralazine induced lupus and sweet's syndrome: report and review of the literature." J Rheumatol, 17, p. 682-4
- Lunde PK, Frislid K, Hansteen V (1977) "Disease and acetylation polymorphism." Clin Pharmacokinet, 2, p. 182-97
- Timbrell JA, Facchini V, Harland SJ, Mansilla-Tinoco R (1984) "Hydralazine-induced lupus: is there a toxic metabolic pathway?" Eur J Clin Pharmacol, 27, p. 555-9
- (2001) "Product Information. Apresoline (hydralazine)." Ciba-Geigy Pharmaceuticals
- Pirmohamed M (1996) "Hydralazine-induced lupus: yet another autoantibody! triplex-DNA stabilization by hydralazine and the presence of anti-(triplex DNA) antibodies in patients treated with hydralazine - comment." Hum Exp Toxicol, 15, p. 361-2
Hydralazine (applies to hydralazine) valvular heart disease
Major Potential Hazard, High plausibility.
The use of hydralazine is contraindicated in patients with mitral valvular rheumatic heart disease.
References
- (2001) "Product Information. Apresoline (hydralazine)." Ciba-Geigy Pharmaceuticals
Hydralazine (applies to hydralazine) cerebral vasculopathy
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cerebral Vascular Disorder
The vasodilatory effects of hydralazine may aggravate cerebral vasculopathy. Therapy with hydralazine should be administered cautiously in patients with cerebral vasculopathy.
References
- Koch-Weser J (1976) "Hydralazine." N Engl J Med, 295, p. 320-3
- (2001) "Product Information. Apresoline (hydralazine)." Ciba-Geigy Pharmaceuticals
Hydralazine (applies to hydralazine) renal dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glomerulonephritis
The use of hydralazine has been associated with the development of glomerulonephritis. Hydralazine should be used with caution in patients with advanced renal damage and these patients may require a lower dose. Renal function should be monitored and supported as required.
References
- (2001) "Product Information. Apresoline (hydralazine)." Ciba-Geigy Pharmaceuticals
Hydralazine drug interactions
There are 397 drug interactions with hydralazine.
Hydralazine alcohol/food interactions
There is 1 alcohol/food interaction with hydralazine.
More about hydralazine
- hydralazine consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (89)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Drug class: vasodilators
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.